
Meeting to be held in London on November 17 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics | 13.60 | -0.22 | -1.61% |
| Name | Price | % Change | |
|---|---|---|---|
| $13.60 | -1.61% |

Meeting to be held in London on November 17 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the

Nurix Therapeutics (NRIX) announced the appointment of Arati Rao as chief medical officer. Rao brings more than 20 years of experience spanning academic hematology and oncology, early- and late-stage clinical

20:18 EST Cathie Wood’s ARK Investment buys 350.4K shares of Nurix Therapeutics (NRIX) today Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

The major averages were sharply higher following Tuesday’s midterm elections, as Democrats retook the Senate and House of Representatives and won multiple state governorships. The conclusion of the midterm elections,

Nurix Therapeutics (NRIX) is down -40.7%, or -$10.51 to $15.31. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks

Nurix Therapeutics (NRIX) is down -39.1%, or -$10.09 to $15.73. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks

Jeet Mukherjee, an analyst from BTIG, reiterated the Buy rating on Nurix Therapeutics. The associated price target remains the same with $32.00. Jeet Mukherjee gave his Buy rating based on

Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $20 from $25 and keeps an Equal Weight rating on the shares. The discontinuation is a negative surprise,

The latest update is out from Nurix Therapeutics ( ($NRIX) ). On November 3, 2026, Sanofi notified Nurix Therapeutics that it was discontinuing the Phase 1 first-in-human clinical trial of

Nurix Therapeutics (NRIX) announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| hold | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Oct 15, 2026 | ||||
| buy | Reiterated | Oct 13, 2026 | ||||
| buy | Reiterated | Oct 13, 2026 | ||||
| buy | Reiterated | Oct 13, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 17, 2027TBA | $1.56B | $-0.43 | $35.79M | -0.94 | 5.62 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.